To be the best,
we work with the best
SkylineDx is on a mission to revolutionize the future of personalized medicine today. In order to make important steps in the conservative landscape we collaborate with academic institutes, hospitals and patient associations that are ahead in their field. The rebels that help us change the landscape.
We are inspired by the many collaborations that prove we are not in the battle alone.
#amazingthingshappen
Erasmus Medical Center (EMC), The Netherlands
We collaborate with the EMC in two different disease areas. The first is a collaboration with the Hematology department led by Professor Dr. Sonneveld, a scientific and clinical partner for our multiple myeloma franchise. The second collaboration is with the Dermatology department led by Professor Dr. Nijsten, a partner for our melanoma franchise.
Erasmus School of Health Policy & Management (ESHPM), The Netherlands
The ESHPM is a research institute specialized in health economics and medical technology assessment. This independent partner in our H2020 research project will study how clinical decision making is impacted by the newly discovered signatures in multiple myeloma and provide cost-effectiveness analyses.
Hackensack UMC in Hackensack, New Jersey, United States
Participating site in our prospective multicenter study to measure the impact of MMprofilerTM on treatment intention in active multiple myeloma patients. Click here for more information about this clinical study, and here for more information about the MMprofilerTM with SKY92.
The Institute of Cancer Research (ICR), United Kingdom
ICR performs MMprofilerTM with SKY92 analyses for a clinical study led by Principal Investigator Dr. Martin Kaiser, hematology practioner at The Royal Marsden in London.
Levine Cancer Institute in Charlotte, North Carolina, United States
Participating site in our prospective multicenter study to measure the impact of MMprofilerTM on treatment intention in active multiple myeloma patients. Click here for more information about this clinical study, and here for more information about the MMprofilerTM with SKY92.
Lombardi Comprehensive Cancer Center in Washington DC, United States
Participating site in our prospective multicenter study to measure the impact of MMprofilerTM on treatment intention in active multiple myeloma patients. Click here for more information about this clinical study, and here for more information about the MMprofilerTM with SKY92.
Mayo Clinic in Rochester, Minnesota, United States
We collaborate with the Department of Dermatology led by Associate Professor Alexander Meves, M.D. on the development of novel diagnostic tests which will improve clinical decision making for melanoma patients. Together with the renowned Mayo Clinic we are able to optimize and further develop an algorithm to identify risk factors associated with metastases.
Medical College of Wisconsin in Milwaukee, Wisconsin, United States
Participating site in our prospective multicenter study to measure the impact of MMprofilerTM on treatment intention in active multiple myeloma patients. Click here for more information about this clinical study, and here for more information about the MMprofilerTM with SKY92.
Monash University, Australia
The head of the Malignant Haematology and Stem Cell Transplantation Service, Professor Spencer, is independently including the MMprofilerTM with SKY92 diagnostic in their clinical studies.
Myeloma Patients Europe (MPE), Belgium
MPE is an umbrella organization of myeloma patient groups and associations from across Europe. This partner provides valuable input from a patient perspective and raises awareness about our joint H2020 research project to patients and caregivers all across large Europe.
National Cancer Institute Singapore (NCIS), Singapore
NCIS, directed by professor Chng, participates as a clinical partner in our H2020 research project by providing multiple myeloma samples and clinical information.
University Medical Center Utrecht (UMCU), The Netherlands
Our scientific collaboration with the UMCU is focused on big data algorithms. The first is a collaboration with the Center for Molecular Medicine led by Principle Investigator / Associate Professor Dr. de Ridder where we are developing machine learning approaches to mine biomarkers from data, named GESTURETM. The second is a collaboration with the corporate program Applied Data Analytics in Medicine (ADAM) led by the Ambassador for eHealth & Big Data Professor Dr. Solinge where we are developing electronic health record (EHR) based algorithms for decision support in the clinic.
University of Turin (UNITO), Italy
In the last 40 years, the Onco-Hematology department of University of Turin's main effort has been on the worldwide improvement of multiple myeloma treatment. UNITO participates as a clinical partner in our H2020 research project by providing multiple myeloma samples, clinical information and valuable input regarding the study design and development.
Weill Cornell Medicine, New York, New York, United States
Participating site in our prospective multicenter study to measure the impact of MMprofilerTM on treatment intention in active multiple myeloma patients. Click here for more information about this clinical study, and here for more information about the MMprofilerTM with SKY92.
Commercial Collaborations:
Everything Genetic Ltd, United Kingdom
Everything Genetic is one of our commercial collaborators. This organization will distribute and market SkylineDx's multiple myeloma solutions in the United Kingdom.